PALO ALTO, Calif., Dec. 2, 2015 /PRNewswire/ -- Ablative Solutions, Inc. (ASI), a venture-backed, privately-held clinical stage company, announced today the addition of Gregg W. Stone, MD, to its Scientific Advisory Board. Dr. Stone is the Director of Cardiovascular Research and Education at the Columbia University Medical Center/New York-Presbyterian Hospital in New York. An internationally recognized interventional cardiologist, Dr. Stone has extensive experience in advancing new innovative technologies through clinical research.
ASI has developed an innovative, patented device, the Peregrine System™ Infusion Catheter. The device has received CE Mark approval, allowing it to be used in Europe to treat hypertensive patients by infusing a neurolytic agent into the perimeter surrounding the renal artery, targeting the sympathetic nerves that contribute to hypertension. The Peregrine System has been 510(k) cleared by the U.S. Food and Drug Administration (FDA) for the infusion of diagnostic and therapeutic agents into the perivascular area; however, it is not currently cleared or approved in the U.S. for the treatment of hypertension.
"Recent publications have suggested that reliably interrupting the sympathetic nerve pathways may have beneficial effects in patients with hypertension," observed Dr. Stone. "I'm encouraged by the extensive pre-clinical and early clinical results of the Peregrine System Catheter, the circumferential nerve ablative effects of Ablative Solutions' targeted infusion, and the device's potential to add clinical value."
In welcoming Dr. Stone to ASI's Scientific Advisory Board, Ablative Solutions Chief Executive and Medical Officer, Tim Fischell, MD, recognized his extensive experience. "We are honored to have Dr. Stone's guidance as our company moves forward with clinical plans for Europe and, in the future, the U.S.," Dr. Fischell stated.
ASI is headquartered in Kalamazoo, MI, with offices in Palo Alto, CA. The company was founded by two proven medical device entrepreneurs, Tim Fischell, MD, and David Fischell, PhD. Development efforts have been led by ASI President Vartan Ghazarossian, PhD, and Tim Fischell, MD, CEO. The Company has pioneered the development of a unique, patented technology, the Peregrine System, to deliver diagnostic and therapeutic agents directly to the perivascular region that surrounds blood vessels.
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of ASI's products to patients, market and physician acceptance of ASI's products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. ASI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information:
Vartan Ghazarossian, PhD
SOURCE Ablative Solutions, Inc.